Introduction
Candida albicans is a widespread and increasingly troublesome opportunistic pathogen causing a variety of superficial and deep-seated mycoses, particularly in immunocompromised and neutropenic patients (Pittet & Wenzel, 1995; Rogers, 1995) . Relatively few antifungal agents are available, particularly for deep-seated Candida mycoses. Amphotericin B and the azole drugs such as itraconazole and ketoconazole are currently used. More recently, flucanozole has been used for C. albicans mycoses though its use is restricted by its limited spectrum of activity and reports of emerging resistance to some Candida isolates.
The fungus is dimorphic and can exist in two clearly identifiable morphologies, namely yeast and hyphal forms. However, the relevance of Candida dimorphism is still far from being understood. Nonetheless, there is evidence that the hyphal form may play a pathogenic role in initial processes of tissue invasion. C. albicans germ tubes and hyphae adhere better than yeast cells to human buccal and vaginal epithelia (Odds, 1988) . Interestingly, although there have been many investigations carried out into the standardization of the antifungal susceptibility testing of C. albicans, those investigations deal with the susceptibility of yeast-phase cells only (NCCLS, 1992; Galgiani, 1993) and do not consider the ability of particular agents in preventing the transformation to germ tubes and hyphae. Consequently, studies into the relationship between activity of different antifungal agents and their effects on the morphogenetic transformation are needed.
Investigations of the morphogenetic transformation from the yeast to the hyphal form are facilitated in vitro by culturing C. albicans at 35°C in defined rich media, while at 25°-28°C the yeast form is predominant (Odds, 1988; Van Cutsem, Van Gervan & Janssen, 1986) . Effects of the imidazoles on C. albicans under such conditions have been studied and it is frequently reported that this class of compound exhibits a pronounced effect on the morphogenetic transformation compared with that on the growth of the yeast form. This effect of azoles, on the morphogenetic transformation, occurs at significantly lower concentrations when compared with amphotericin B (Van Cutsem et al., 1986; Jansen et al., 1991) . By contrast, other studies have indicated that germ tube formation may be diminished in the presence of imidazole agents although it is not completely blocked (Johnson et al., 1982; Johnson, Richardson & Warnock, 1983) .
We have therefore undertaken a study on the morphogenetic transformation using several culture conditions. The effect of several antifungal agents, with different mechanisms of action, has been examined using synchronised yeast-phase Candida cells and their respective anti-Candida and anti-morphogenetic transformation activities have been determined.
Materials and methods

Organisms
Synchronised yeast-phase Candida cells were used in all experiments (Hawser & Islam, 1996) . C. albicans ATCC 10231, C. albicans reference strains ATCC 90028 and ATCC 90029 (NCCLS, 1992) and C. albicans clinical isolate SKF 2270 were used throughout this study. All stock cultures were maintained freeze-dried at +4°C in closed glass vials. Synchronised stationary phase yeast cultures of C. albicans were obtained as follows. Freeze-dried stock cultures were resuspended in 0.1 M phosphate-buffered saline (pH 7.2), inoculated into Minimal-40 medium at 1 x 10 5 cells/mL and incubated at 25°C for 48 h without agitation. This yielded 1-2 x 10* synchronous stationary yeast-phase Candida cells/mL. The synchronicity of Candida cells, with respect to the morphogenetic transformation, was confirmed by inoculating 1.5 x 10 3 or 2 x 10 4 cells/ mL into RPMI-1640 medium or medium containing 20% horse serum at 35°C. Under these conditions, >99% of Candida cells produced germ tubes. Thereafter, Candida cells were harvested, washed three times in 0.1 M phosphate-buffered saline and used immediately in MIC and morphogenetic transformation assays.
Minimal inhibitory concentration (MIC) determinations
The MICs were performed using different growth media: RPMI-1640 with L-glutamine (Gibco, Paisley, UK) and containing 2 g of glucose per litre, buffered with 0.15 M MOPS to pH 7.0; Medium-199 (Gibco) with Earle's salts containing 20 mM HEPES buffer, pH 7.0; Sabouraud dextrose broth (pH 5.6; Difco, Detroit, MI, USA); Minimal medium 40 (pH 6.8). For MIC determinations, synchronised yeast-phase Candida were added into wells of flat-bottomed 96 well tissue culture plates (Nunclon, Neperville, IL, USA) as an inoculum of 2 x lO^ells/mL in different media and incubated for 48 h at 25°C or 35°C.
In similar experiments, a modification of the NCCLS proposed standard for the antifungal susceptibility testing of yeasts (NCCLS, 1992) was employed by using an inoculum of 1.5 x 10 3 cells/mL, RPMI-1640 medium and incubation for 48 h at 35°C. Antifungal agents were added to appropriate wells as final concentrations of 0.003-256 mg/L. MIC values were determined following incubation for 48 h at 35 C C only (NCCLS modification; inoculum 1.5 x 10 3 cells/mL) or 25°C and 35°C (inoculum 2 x lO'cells/mL). MIC end-points were read as the lowest concentration of antifungal agent which prevented any discernible growth. All MIC experiments were performed three times.
Morphogenetic transformation experiments
The effects of several antifungal agents on the morphogenetic transformation were also investigated by microscopy. Synchronised cells were added to wells of 96 well tissue culture plates in 100 /JL of appropriate medium as inocula of 1.5 x 10 3 or 2x10* cells/mL. Thereafter, for each antifungal (0.003-256 mg/L) and strain tested the highest concentration of antifungal agent at which the morphogenetic transformation was observed was recorded. Observations were made after 4 and 24 h (2 x 10 4 cells/mL) or 24 and 48 h (1.5 x 10 3 cells/mL) incubation at 35°C. In control experiments at 35°C, cells which were not challenged with antifungal agents were used. All experiments were performed three times in triplicate.
Microscopy
The morphogenetic transformation and the effects of antifungal agents were routinely examined using either an inverted Olympus CK. microscope and when required in more detail using a Zeiss phase-contrast microscope. Yeast-phase, initial germ tube, pseudohyphal and hyphal morphologies were scored as defined by Odds (1988) . The entire population of cells in the wells, either 1.5 x 10 3 or 2 x 10* cells/mL, were examined and control cultures at 25°C consisted of >99% yeast-phase cells while those grown at 35°C consisted of >99% germ tubes. The effects of antifungal agents on the morphogenetic transformation were also examined by microscopy. Once again, the entire population in the wells was examined and the highest concentration of antifungal agent used at which the morphogenetic transformation from the yeast to germ tube form occurred was recorded. Typically, lack of inhibition of germ tube formation resulted in a tangled mass of hyphae after 24 and 48 h incubation at 35°C.
Antifungal agents and chemicals
The following antifungal agents were used: itraconazole, ketoconazole and miconazole were purchased from Janssen Pharmaceutica, Beerse, Belgium; amphotericin B, flucytosine and tunicamycin were purchased from Sigma Chemical Co., St. Louis, MO, USA; fluconazole was purchased from Pfizer, Sandwich, United Kingdom; echinocandin was a kind gift from Dr J. Sanglier, Sandoz, Basle, Switzerland. All antifungal agents were dissolved in dimethyl sulphoxide with the exception of flucytosine and echinocandin which were dissolved in sterile distilled water or ethanol, respectively. These solvents did not affect the morphogenetic transformation at the concentrations used in the assays (<2% v/v). MOPS and dimethyl sulphoxide were from Sigma.
Results
MIC determinations
Synchronised yeast-phase Candida cells were highly susceptible to the azoles (MIC <,0.05 mg/L), amphotericin B (MIC 0.02-0.08 mg/L) and echinocandin (MIC 0.01-0.01 mg/L). By contrast, Candida cells were less susceptible to flucytosine (MIC 0.05-1.6 mg/L) and tunicamycin (MIC 0.16-1.25 mg/L). MIC values were similar for each antifungal agent regardless of C. albicans strain used and only values for strain ATCC 10231 are shown (Table I ). However, growth medium and incubation temperature employed did result in some variation betwen MIC values. For example, values for the azoles, amphotericin B and echinocandin did not vary irrespective of medium or temperature (Table I ). In contrast, tunicamycin was generally more active at 35°C compared with 25°C irrespective of medium used. Furthermore, flucytosine was less active in tissue culture media (RPMI-1640 and Medium-199) when compared with Minimal-40 medium and was inactive against the flucytosine-resistant C. albicans ATCC 90029 (NCCLS, 1992) .
In a separate series of experiments which approximated more closely to the NCCLS proposed standard procedure, synchronisesd yeast-phase Candida cells were inoculated into wells at 1.5 x 10 3 cells/mL in RPMI-1640 medium and MIC tests performed at 35°C only (Table II) . Amphotericin B and ketoconazole were equally active against Candida cells (MIC 0.03-0.06 mg/L) (Table II) . In contrast, fluconazole and flucytosine exhibited similar activities against the Candida strains (MIC 0.03-0.5 mg/L). Furthermore, the resistance of C. albicans ATCC 90029 cells to flucytosine (NCCLS, 1992) was confirmed (Table II) .
Quantitative evaluation of antifungal agents on the morphogenetic transformation
Amphotericin B inhibited the morphogenetic transformation at low concentrations (4 h: 0.02-0.08 mg/L and 24 h: 0.04-0.15 mg/L). Amphotericin B showed similar activity regardless of the medium used (Table III) . Comparable results were also observed for tunicamycin and echinocandin (Table III) . By contrast, the azoles were only able to block the formation of germ tubes at high concentrations: itraconazole (4 h: 6.25-50 mg/L and 24 h: 6.25-50 mg/L), ketoconazole (4 h: 6.25-25 mg/L and 24 h: 6.25-50 mg/L) and miconazole (4 h: 6.25-12.5 mg/L and 24 h: 6.25-25 mg/L). The effect of the azoles on the morphogenetic transformation was significantly less (P < 0.001) than amphotericin B (Table III) . However, a separate series of experiments showed that, following 24 h incubation at 25°C with the MIC for either amphotericin B or ketoconazole, no growth of yeasts had occurred and at this concentration neither antifungal agent was fungicidal (data not shown). Furthermore, flucytosine was incapable of preventing germ tube formation even at high concentrations ( > 50 mg/L) ( Table III) . Under these experimental conditions the data were similar irrespective of the C. albicans strain used.
The effects of antifungal agents on the morphogenetic transformation was also investigated using a microtitre plate assay which approximated closely to the parameters used in the NCCLS proposed standard procedure for yeast susceptibility testing. (Table IV) . Once again, The procedure was carried out in different media, at 25° or 35°C and with an inoculum of V x 10 synchronised yeasts/mL. Data is representative of the four different C. albicans strains whereby no significant differences between the strains were recorded under these conditions. The only exception was strain ATCC 90029 which was resistant to flucytosine (data not shown). Values represent the minimum inhibitory concentration (mg/L) for each antifungal agent after 48 h incubation at either 25 or 35°C. *Some microgrowth was observed at these concentrations. ketoconazole (24 and 48 h: 8-16 mg/L) and fluconazole (24 h: 8 mg/L and 48 h: 4-8 mg/L) were only able to inhibit the formation of germ tubes at much higher concentrations (Table IV) , the effect of the azoles was again significantly less (P < 0.001) than amphotericin B (Table IV) . In contrast, flucytosine was only able to block germ tube formation when used at high concentrations ( ^ 32 mg/L) ( Table IV) .
Discussion
Although many investigations describing the parameters and conditions for antifungal susceptibility testing of yeasts have been performed (Espinell-Ingroff et al., 1992; Galgiani, 1993; Rex et al., 1993; Barchiesi et al., 1994) , few studies have consolidated the relationship between antifungal activities per se and the effects of antifungal agents on the morphogenetic transformation by C. albicans in vitro. In this investigation we have performed experiments with synchronous C. albicans cells using a variety of test conditions, including parameters which approximated to those defined by the NCCLS.
Data from the different MIC experiments demonstrated that the azoles, amphotericin B and echinocandin were the most active antifungal agents against the four C. albicans strains. Furthermore, the values obtained for the different antifungal agents typically fell within the acceptable range of activity described in the NCCLS proposed standard procedure for antifungal susceptibility testing of yeasts. Moreover, there was some variation between MIC values when experiments were performed using different growth media, inoculum size and incubation temperature. These findings substantiate those from separate investigations which have described aberration in the activities of several classes of antifungal agents, with different mechanisms of action, attributed to various MIC test parameters (NCCLS, 1992; Rex et al., 1993) .
The use of MIC methodologies, such as that proposed by the NCCLS and applied since, have been useful to some extent. However, such methodology does not confront the issue of which classes of antifungal agents prevent the morphogenetic transformation from the yeast to hyphal form by, for example, C. albicans and other dimorphic fungi. The morphogenetic transformation experiments performed in the present study have shown that amphotericin B prevented the transformation, under a variety of test conditions, more than the azoles and flucytosine. Interestingly, amphotericin B prevented the transformation at, and significantly below the corresponding MIC value. In contrast, the azole antifungal agents prevented the transformation at concentrations which were significantly higher than the corresponding MIC values. Our data are in contrast with earlier studies describing the inhibition of the morphogenetic transformation at concentrations at and moderately below their MIC activities for azole agents (Odds et al., 1985; Van Cutsem et al., 1986) . For example, in the study by Van Cutsem et al. (1986) , amphotericin B was shown to prevent the morphogenetic transformation by C. albicans, in tissue culture medium, at 1.0 mg/L but was unable to do so at 0.2 mg/L. In contrast, we have demonstrated that, by using NCCLS guidelines and tissue culture medium, amphotericin B blocked the morphogenetic transformation at concentrations of 0.0125-0.03 mg/L, for the four strains tested, after 48 h incubation. In addition, we also demonstrated that, by using NCCLS conditions, ketoconazole prevented the morphogenetic transformation at concentrations of 8-16 mg/L. Van Cutsem et al. (1986) claimed that ketoconazole completely blocked the morphogenetic transformation at 0.0016 mg/L and itraconazole at 30 nM has been reported to prevent the morphogenetic transformation by C. albicans whilst allowing growth of the yeast form (Vanden Bossche, 1995) . However, our data, although performed under different conditions, would be more in agreement with those described by Johnson et al. (1982 Johnson et al. ( , 1983 who showed that azole agents do not block the morphogenetic transformation but can diminish the rate of germ tube elongation.
Considering the importance of antifungal susceptibility testing of dimorphic fungi, including C. albicans, it is important to measure quantitatively the effects of various antifungal agents with different mechanisms of action on the morphogenetic transformation by the organism. Our investigation has illustrated several significant differences in the activities of different antifungal agents in both MIC and morphogenetic transformation experiments.
By analogy with different methodologies employed for MIC testing and the inter-laboratory agreement generated on MIC data using the NCCLS proposed guidelines it may prove useful to standardize experiments that describe the effects of antifungal agents on the morphogenetic transformation using a modification of the NCCLS procedure such as that described in this paper.
